{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T04:47:11Z","timestamp":1773809231417,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100009594","name":"P\u00e9csi Tudom\u00e1nyegyetem","doi-asserted-by":"publisher","award":["20765\/3\/2018\/FEKUSTRAT"],"award-info":[{"award-number":["20765\/3\/2018\/FEKUSTRAT"]}],"id":[{"id":"10.13039\/501100009594","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011019","name":"Nemzeti Kutat\u00e1si Fejleszt\u00e9si \u00e9s Innov\u00e1ci\u00f3s Hivatal","doi-asserted-by":"publisher","award":["EFOP - 3.6.2-16-2017-00008"],"award-info":[{"award-number":["EFOP - 3.6.2-16-2017-00008"]}],"id":[{"id":"10.13039\/501100011019","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011019","name":"Nemzeti Kutat\u00e1si Fejleszt\u00e9si \u00e9s Innov\u00e1ci\u00f3s Hivatal","doi-asserted-by":"publisher","award":["SNN125143"],"award-info":[{"award-number":["SNN125143"]}],"id":[{"id":"10.13039\/501100011019","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011019","name":"Nemzeti Kutat\u00e1si Fejleszt\u00e9si \u00e9s Innov\u00e1ci\u00f3s Hivatal","doi-asserted-by":"publisher","award":["\u00daNKP - 17- 4"],"award-info":[{"award-number":["\u00daNKP - 17- 4"]}],"id":[{"id":"10.13039\/501100011019","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005881","name":"Emberi Eroforr\u00e1sok Miniszt\u00e9riuma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005881","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","prd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism & Related Disorders"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.parkreldis.2019.01.005","type":"journal-article","created":{"date-parts":[[2019,1,4]],"date-time":"2019-01-04T19:07:10Z","timestamp":1546628830000},"page":"117-121","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Trimetazidine and parkinsonism: A prospective study"],"prefix":"10.1016","volume":"62","author":[{"given":"D\u00e1vid","family":"Pint\u00e9r","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e1rton","family":"Kov\u00e1cs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e1rk","family":"Harmat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annam\u00e1ria","family":"Juh\u00e1sz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f3zsef","family":"Janszky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7332-9240","authenticated-orcid":false,"given":"Norbert","family":"Kov\u00e1cs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.parkreldis.2019.01.005_bib1","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1093\/eurheartj\/eht296","article-title":"ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology","volume":"34","author":"Montalescot","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.parkreldis.2019.01.005_bib2","series-title":"National Survey on Drug Use","author":"The National Health Insurance Fund of Hungary","year":"2018"},{"key":"10.1016\/j.parkreldis.2019.01.005_bib3","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.parkreldis.2019.01.005_bib4","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/bdd.350","article-title":"Pharmacokinetic profile of a modified release formulation of trimetazidine (TMZ MR 35 mg) in the elderly and patients with renal failure","volume":"24","author":"Barre","year":"2003","journal-title":"Biopharm Drug Dispos."},{"key":"10.1016\/j.parkreldis.2019.01.005_bib5","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2515\/therapie:2005061","article-title":"Trimetazidine induces parkinsonism, gait disorders and tremor","volume":"60","author":"Marti Masso","year":"2005","journal-title":"Therapie"},{"key":"10.1016\/j.parkreldis.2019.01.005_bib6","first-page":"392","article-title":"Trimetazidine-induced parkinsonism","volume":"19","author":"Marti Masso","year":"2004","journal-title":"Neurologia"},{"key":"10.1016\/j.parkreldis.2019.01.005_bib7","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1002\/mds.20574","article-title":"Trimetazidine: a new cause for drug-induced parkinsonism?","volume":"20","author":"Sommet","year":"2005","journal-title":"Mov. Disord.: Offic. J. Mov. Dis. Soc."},{"key":"10.1016\/j.parkreldis.2019.01.005_bib8","doi-asserted-by":"crossref","first-page":"603","DOI":"10.2515\/therapie:2005090","article-title":"Trimetazidine-a new aetiology for extrapyramidal disorders: a case of parkinsonism and akathisia","volume":"60","author":"Masmoudi","year":"2005","journal-title":"Therapie"},{"key":"10.1016\/j.parkreldis.2019.01.005_bib9","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.revmed.2007.12.001","article-title":"Trimetazidine-induced encephalopathy with choreiform disorders: a case report","volume":"29","author":"Sivet","year":"2008","journal-title":"Rev. Med. Interne"},{"key":"10.1016\/j.parkreldis.2019.01.005_bib10","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/j.1472-8206.2011.01008.x","article-title":"Extrapyramidal adverse drug reactions associated with trimetazidine: a series of 21 cases","volume":"26","author":"Masmoudi","year":"2012","journal-title":"Fundam. Clin. Pharmacol."},{"key":"10.1016\/j.parkreldis.2019.01.005_bib11","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1002\/mds.23828","article-title":"Drug-induced parkinsonism: a review of 17 years' experience in a regional pharmacovigilance center in France","volume":"26","author":"Bondon-Guitton","year":"2011","journal-title":"Mov. Disord.: Offic. J. Mov. Dis. Soc."},{"key":"10.1016\/j.parkreldis.2019.01.005_bib12","series-title":"European Medicines Agency Recommends Restricting Use of Trimetazidine-Containing Medicines","year":"2012"},{"key":"10.1016\/j.parkreldis.2019.01.005_bib13","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/s40265-014-0233-5","article-title":"Defining the role of trimetazidine in the treatment of cardiovascular disorders: some insights on its role in heart failure and peripheral artery disease","volume":"74","author":"Chrusciel","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.parkreldis.2019.01.005_bib14","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/jcbfm.1995.63","article-title":"D2 receptor blockade by flunarizine and cinnarizine explains extrapyramidal side effects. A SPECT study","volume":"15","author":"Brucke","year":"1995","journal-title":"J. Cerebr. Blood Flow Metabol. : Offic. J. Int. Soc. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.parkreldis.2019.01.005_bib15","doi-asserted-by":"crossref","first-page":"686304","DOI":"10.1155\/2013\/686304","article-title":"Antipsychotic-like effect of trimetazidine in a rodent model","volume":"2013","author":"Erbas","year":"2013","journal-title":"TheScientificWorldJOURNAL"},{"key":"10.1016\/j.parkreldis.2019.01.005_bib16","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1002\/mds.22340","article-title":"Movement disorder society-sponsored revision of the unified Parkinson's disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results","volume":"23","author":"Goetz","year":"2008","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2019.01.005_bib17","first-page":"129","article-title":"Validation of the Hungarian MDS-UPDRS: why do we need a new Parkinson scale?","volume":"67","author":"Horv\u00e1th","year":"2014","journal-title":"Ideggyogyaszati Szle."},{"key":"10.1016\/j.parkreldis.2019.01.005_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000455863","article-title":"Changes in quality of life in Parkinson's disease: how large must they Be to Be relevant?","volume":"48","author":"Horvath","year":"2017","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.parkreldis.2019.01.005_bib19","doi-asserted-by":"crossref","first-page":"983606","DOI":"10.1155\/2015\/983606","article-title":"Screening mild and major neurocognitive disorders in Parkinson's disease","volume":"2015","author":"Lucza","year":"2015","journal-title":"Behav. Neurol."},{"key":"10.1016\/j.parkreldis.2019.01.005_bib20","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3233\/JPD-150726","article-title":"Lille apathy rating scale and MDS-UPDRS for screening apathy in Parkinson's disease","volume":"6","author":"Weintraut","year":"2016","journal-title":"J. Parkinson's Dis."},{"key":"10.1016\/j.parkreldis.2019.01.005_bib21","doi-asserted-by":"crossref","first-page":"1470149","DOI":"10.1155\/2017\/1470149","article-title":"Prevalence of anxiety among Hungarian subjects with Parkinson's disease","volume":"2017","author":"Kovacs","year":"2017","journal-title":"Behav. Neurol."},{"key":"10.1016\/j.parkreldis.2019.01.005_bib22","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.parkreldis.2012.02.010","article-title":"Sensitivity and specificity of addenbrooke's cognitive examination, mattis dementia rating scale, frontal assessment battery and mini mental state examination for diagnosing dementia in Parkinson's disease","volume":"18","author":"Kaszas","year":"2012","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.parkreldis.2019.01.005_bib23","first-page":"7951840","article-title":"Impact of sex on the nonmotor symptoms and the health-related quality of life in Parkinson's disease","volume":"2016","author":"Kovacs","year":"2016","journal-title":"Parkinsons Dis."},{"key":"10.1016\/j.parkreldis.2019.01.005_bib24","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.parkreldis.2014.10.026","article-title":"Parkinson's disease severity levels and MDS-Unified Parkinson's Disease Rating Scale","volume":"21","author":"Martinez-Martin","year":"2015","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.parkreldis.2019.01.005_bib25","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/mds.25383","article-title":"How to identify tremor dominant and postural instability\/gait difficulty groups with the movement disorder society unified Parkinson's disease rating scale: comparison with the unified Parkinson's disease rating scale","volume":"28","author":"Stebbins","year":"2013","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2019.01.005_bib26","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.parkreldis.2016.06.001","article-title":"Validation of an automated morphological MRI-based (123)I-FP-CIT SPECT evaluation method","volume":"29","author":"Perlaki","year":"2016","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.parkreldis.2019.01.005_bib27","doi-asserted-by":"crossref","first-page":"e222","DOI":"10.1016\/j.archger.2010.11.025","article-title":"Cognitive dysfunction in drug induced parkinsonism (DIP)","volume":"53","author":"Kim","year":"2011","journal-title":"Arch. Gerontol. Geriatr."},{"key":"10.1016\/j.parkreldis.2019.01.005_bib28","first-page":"108","article-title":"Towards better patient care: drugs to avoid","volume":"22","year":"2013","journal-title":"Prescrire Int."},{"key":"10.1016\/j.parkreldis.2019.01.005_bib29","doi-asserted-by":"crossref","first-page":"89","DOI":"10.5152\/akd.2014.5866","article-title":"Primum non nocere","volume":"15","author":"Ureyen","year":"2015","journal-title":"Anatol. J. Cardiol."}],"container-title":["Parkinsonism & Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802019300057?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802019300057?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:15:56Z","timestamp":1761178556000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802019300057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":29,"alternative-id":["S1353802019300057"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2019.01.005","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trimetazidine and parkinsonism: A prospective study","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2019.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}